Current models of T cell memory implicate a critical role for IL-7 in the effector-to-memory
transition, raising the possibility that IL-7 therapy might enhance vaccine responses. IL-7 has …

In this review, we describe the evidence from which the existence of non-MHC
histocompatibility (H) antigens was deduced, the clinical setting of bone marrow …

Activated T cells require increased energy to proliferate and mediate effector functions, but
the metabolic changes that occur in T cells following stimulation in vivo are poorly …

Adoptive transfer of T cells reactive to minor histocompatibility antigens has the unmatched
ability to eradicate malignant hematopoietic cells. Unfortunately, its use is hampered by the …

In this review, we describe the evidence from which the existence of non‐MHC
histocompatibility (H) antigens was deduced, the clinical setting of bone marrow …

The H60 minor histocompatibility (H) antigen peptide is derived from a glycoprotein that
serves as a ligand for the stimulatory NKG2D receptor. We show that this peptide is …

T cells responsive to minor histocompatibility (H) antigens are extremely effective in curing
leukemia but it remains unknown whether they can eradicate solid tumors. We report that …

Minor histocompatibility Ags (minor H Ags) are substantial impediments to MHC-matched
solid tissue and bone marrow transplantation. From an antigenic standpoint, transplantation …

Allogeneic bone marrow transplantation (BMT) induces 2 closely associated immune
responses: graft-versus-tumor (GVT) activity and graft-versus-host disease (GVHD). We …

The goal of this work was to evaluate the fate of APCs following interactions with T cells in
unprimed mice with a normal T cell repertoire. We elaborated a model in which male …